Kebuzone

Identification

Name
Kebuzone
Accession Number
DB08940
Type
Small Molecule
Groups
Experimental
Description

Kebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.

Structure
Thumb
Synonyms
  • ketophenylbutazone
Categories
UNII
4VD83UL6Y6
CAS number
853-34-9
Weight
Average: 322.3578
Monoisotopic: 322.131742452
Chemical Formula
C19H18N2O3
InChI Key
LGYTZKPVOAIUKX-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3
IUPAC Name
4-(3-oxobutyl)-1,2-diphenylpyrazolidine-3,5-dione
SMILES
CC(=O)CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 5-androstenedione.Experimental, Illicit
AbciximabKebuzone may increase the anticoagulant activities of Abciximab.Approved
AcebutololKebuzone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Kebuzone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolKebuzone may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Kebuzone.Approved, Vet Approved
AclarubicinKebuzone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Kebuzone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Aldosterone.Experimental, Investigational
AldoxorubicinKebuzone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.Approved
AliskirenKebuzone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alminoprofen.Experimental
AlprenololKebuzone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Kebuzone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Amcinonide.Approved
AmikacinKebuzone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideKebuzone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinKebuzone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodKebuzone may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Kebuzone.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Kebuzone is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Kebuzone is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Anisodamine.Investigational
AnnamycinKebuzone may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Kebuzone.Approved
Antithrombin III humanKebuzone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanKebuzone may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Kebuzone is combined with Apocynin.Investigational
ApramycinKebuzone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Kebuzone.Approved, Investigational
ArbekacinKebuzone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinKebuzone may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanKebuzone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololKebuzone may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Atamestane.Investigational
AtenololKebuzone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Kebuzone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Kebuzone.Approved
BalsalazideKebuzone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminKebuzone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololKebuzone may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinKebuzone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Kebuzone.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Kebuzone.Approved
BenorilateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Kebuzone.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Kebuzone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Betamethasone.Approved, Vet Approved
BetaxololKebuzone may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Kebuzone.Approved, Investigational
BevantololKebuzone may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Kebuzone.Approved, Investigational
BisoprololKebuzone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinKebuzone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololKebuzone may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Kebuzone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bucillamine.Investigational
BucindololKebuzone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bufexamac.Experimental
BufuralolKebuzone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bumadizone.Experimental
BumetanideKebuzone may decrease the diuretic activities of Bumetanide.Approved
BupranololKebuzone may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Kebuzone.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Kebuzone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Kebuzone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Kebuzone.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Kebuzone is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Kebuzone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Kebuzone.Approved, Vet Approved, Withdrawn
CarteololKebuzone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolKebuzone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Kebuzone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Kebuzone.Approved, Investigational
CeliprololKebuzone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinKebuzone may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Kebuzone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Kebuzone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Kebuzone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Kebuzone.Approved
CinoxacinKebuzone may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidKebuzone may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Kebuzone.Vet Approved
CloranololKebuzone may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Kebuzone is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Kebuzone.Experimental
CyclosporineKebuzone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateKebuzone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinKebuzone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidKebuzone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanKebuzone may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinKebuzone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Kebuzone is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Kebuzone is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Kebuzone.Experimental
DesirudinKebuzone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Kebuzone.Approved, Investigational
DextranKebuzone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Kebuzone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Kebuzone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Kebuzone may increase the anticoagulant activities of Dextran 75.Approved
DibekacinKebuzone may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Kebuzone.Approved, Vet Approved
DicoumarolKebuzone may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Kebuzone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Kebuzone.Approved
DihydrostreptomycinKebuzone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Kebuzone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Kebuzone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Kebuzone.Approved
DoxorubicinKebuzone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneKebuzone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Kebuzone is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Kebuzone is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Kebuzone is combined with E-6201.Investigational
Edetic AcidKebuzone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanKebuzone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Kebuzone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Kebuzone.Approved
EnoxacinKebuzone may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinKebuzone may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Kebuzone.Experimental
EpanololKebuzone may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Kebuzone is combined with Epirizole.Approved
EpirubicinKebuzone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneKebuzone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Kebuzone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Kebuzone.Approved
EquileninThe risk or severity of adverse effects can be increased when Kebuzone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Equilin.Approved
EsmololKebuzone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Estrone sulfate.Approved
Etacrynic acidKebuzone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Kebuzone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ethenzamide.Experimental
Ethyl biscoumacetateKebuzone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Kebuzone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Kebuzone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Kebuzone is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Kebuzone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Kebuzone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Kebuzone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Kebuzone.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Feprazone.Experimental
Ferulic acidKebuzone may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Kebuzone.Approved, Investigational
FleroxacinKebuzone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Kebuzone.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fludrocortisone.Approved
FluindioneKebuzone may increase the anticoagulant activities of Fluindione.Investigational
FlumequineKebuzone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Kebuzone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Kebuzone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Kebuzone.Approved, Nutraceutical, Vet Approved
FondaparinuxKebuzone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumKebuzone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Kebuzone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Kebuzone.Approved
FramycetinKebuzone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideKebuzone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateKebuzone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinKebuzone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinKebuzone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Kebuzone.Approved, Withdrawn
GemifloxacinKebuzone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinKebuzone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinKebuzone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AKebuzone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Kebuzone may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinKebuzone may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Kebuzone is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Kebuzone is combined with HE3286.Investigational
HeparinKebuzone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Higenamine.Investigational
HydralazineKebuzone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Kebuzone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Kebuzone.Approved, Investigational
Hygromycin BKebuzone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Kebuzone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Kebuzone.Approved
IdarubicinKebuzone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxKebuzone may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Kebuzone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Kebuzone.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone.Approved
IndenololKebuzone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Kebuzone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Kebuzone.Approved, Investigational
IsepamicinKebuzone may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Kebuzone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Kebuzone is combined with Istaroxime.Investigational
KanamycinKebuzone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Kebuzone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Kebuzone.Approved
LabetalolKebuzone may decrease the antihypertensive activities of Labetalol.Approved
LandiololKebuzone may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Kebuzone.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Kebuzone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Kebuzone.Approved, Investigational
LepirudinKebuzone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanKebuzone may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololKebuzone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinKebuzone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Kebuzone.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Kebuzone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Kebuzone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Kebuzone.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Kebuzone.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Kebuzone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Kebuzone.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Kebuzone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Kebuzone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Kebuzone.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Kebuzone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Kebuzone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Kebuzone.Approved
MelagatranKebuzone may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Kebuzone.Approved, Vet Approved
MepindololKebuzone may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineKebuzone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Kebuzone.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Kebuzone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololKebuzone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone.Approved
MetoprololKebuzone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideKebuzone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinKebuzone may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Kebuzone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Kebuzone.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Kebuzone.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Kebuzone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Kebuzone.Approved
NadololKebuzone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinKebuzone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatKebuzone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Kebuzone.Approved
Nalidixic AcidKebuzone may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Kebuzone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Kebuzone is combined with NCX 1022.Investigational
NeamineKebuzone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololKebuzone may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinKebuzone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinKebuzone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Kebuzone.Approved
NetilmicinKebuzone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Kebuzone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Kebuzone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Nitroaspirin.Investigational
NorfloxacinKebuzone may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Kebuzone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Kebuzone.Approved
OlsalazineKebuzone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Kebuzone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Kebuzone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Orgotein.Vet Approved
OtamixabanKebuzone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Kebuzone.Approved
Oxolinic acidKebuzone may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololKebuzone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Kebuzone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Kebuzone.Approved
ParomomycinKebuzone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Parthenolide.Investigational
PazufloxacinKebuzone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinKebuzone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololKebuzone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateKebuzone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateKebuzone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Kebuzone.Approved
PhenindioneKebuzone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonKebuzone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Kebuzone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Kebuzone.Approved, Investigational
PindololKebuzone may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidKebuzone may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinKebuzone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideKebuzone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Kebuzone.Approved, Investigational
Piromidic acidKebuzone may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Kebuzone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pirprofen.Experimental
Platelet Activating FactorKebuzone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinKebuzone may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinKebuzone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Kebuzone.Approved
PractololKebuzone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Kebuzone.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Kebuzone can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Propacetamol.Approved, Investigational
PropranololKebuzone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Kebuzone.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Kebuzone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Kebuzone.Vet Approved
Protein CKebuzone may increase the anticoagulant activities of Protein C.Approved
Protein S humanKebuzone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeKebuzone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinKebuzone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Kebuzone.Investigational
PuromycinKebuzone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Kebuzone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Kebuzone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Kebuzone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Kebuzone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Kebuzone.Approved, Experimental, Investigational
ReviparinKebuzone may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinKebuzone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Risedronate.Approved, Investigational
RivaroxabanKebuzone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Kebuzone.Investigational, Withdrawn
RosoxacinKebuzone may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinKebuzone may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinKebuzone may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Kebuzone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Kebuzone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Kebuzone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Kebuzone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Kebuzone.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Kebuzone.Approved
SemapimodThe risk or severity of adverse effects can be increased when Kebuzone is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Kebuzone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Kebuzone is combined with Serrapeptase.Investigational
SisomicinKebuzone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinKebuzone may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Kebuzone.Approved
SotalolKebuzone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CKebuzone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinKebuzone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinKebuzone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Kebuzone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Kebuzone.Investigational
StreptomycinKebuzone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinKebuzone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Kebuzone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Kebuzone.Approved
SulodexideKebuzone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Kebuzone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Kebuzone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Suxibuzone.Experimental
TacrolimusKebuzone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Kebuzone.Approved
TalinololKebuzone may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Kebuzone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Kebuzone.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Kebuzone.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Kebuzone is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Kebuzone.Approved, Investigational
TemafloxacinKebuzone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Kebuzone.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Kebuzone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Kebuzone.Approved
TertatololKebuzone may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Kebuzone.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololKebuzone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tixocortol.Approved, Withdrawn
TobramycinKebuzone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Kebuzone.Approved
TorasemideKebuzone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Kebuzone.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Kebuzone.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Kebuzone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Kebuzone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneKebuzone may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Kebuzone.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triptolide.Investigational
TrovafloxacinKebuzone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinKebuzone may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Kebuzone.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Kebuzone.Investigational, Withdrawn
ValrubicinKebuzone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Kebuzone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Kebuzone.Approved
WarfarinKebuzone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranKebuzone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Kebuzone.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Kebuzone.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Kebuzone.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Kebuzone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Kebuzone.Withdrawn
Zoptarelin doxorubicinKebuzone may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinKebuzone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Maurer HH, Tauvel FX, Kraemer T: Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. J Anal Toxicol. 2001 May-Jun;25(4):237-44. [PubMed:11386636]
External Links
Human Metabolome Database
HMDB41914
KEGG Drug
D01567
PubChem Compound
3824
PubChem Substance
310264907
ChemSpider
3692
ChEBI
31749
ChEMBL
CHEMBL2107720
ATC Codes
M01AA06 — Kebuzone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.113 mg/mLALOGPS
logP1.99ALOGPS
logP2.7ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.17ChemAxon
pKa (Strongest Basic)-7.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area57.69 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity89.37 m3·mol-1ChemAxon
Polarizability33.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Pyrazolidinones / 1,3-dicarbonyl compounds / Ketones / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Pyrazolidinone / 1,3-dicarbonyl compound / Pyrazolidine / Carboxylic acid hydrazide / Ketone / Organoheterocyclic compound / Carboxylic acid derivative / Azacycle / Organic oxide
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazolidines, methyl ketone (CHEBI:31749)

Drug created on May 26, 2014 15:08 / Updated on November 09, 2017 04:42